Tvardi Therapeutics (TVRD) Stock Price, News & Analysis

Company Overview

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Key Stats

• Today's Range: $29.07 to $31.54
• 50-Day Range: $21.45 to $30.59
• 52-Week Range: $8.13 to $34.31
• Volume: 11,956 shs
• Average Volume: 33,213 shs
• Market Capitalization: $288.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $64.25
• Consensus Rating: Buy

Tvardi Therapeutics Stock Analysis - MarketRank™

Tvardi Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 806th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tvardi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tvardi Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Tvardi Therapeutics has a P/B Ratio of 8.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TVRD.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tvardi Therapeutics does not currently pay a dividend.

Dividend Growth

Tvardi Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for TVRD.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.85

News Sentiment

Tvardi Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Tvardi Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for TVRD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Tvardi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Tvardi Therapeutics is held by insiders.

Percentage Held by Institutions

44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TVRD Stock Analysis - Frequently Asked Questions

How have TVRD shares performed this year?

Tvardi Therapeutics' stock was trading at $29.09 at the start of the year. Since then, TVRD shares have increased by 6.8% and is now trading at $31.07.

How were Tvardi Therapeutics' earnings last quarter?

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) released its earnings results on Thursday, August, 14th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.49. Tvardi Therapeutics had a negative net margin of 678.79% and a negative trailing twelve-month return on equity of 565.83%.

Who are Tvardi Therapeutics' major shareholders?

Top institutional investors of Tvardi Therapeutics include Slate Path Capital LP (7.52%), 683 Capital Management LLC (1.88%), Geode Capital Management LLC (1.20%) and Marshall Wace LLP (0.27%).

How do I buy shares of Tvardi Therapeutics?

Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TVRD
• Previous Symbol: NASDAQ:TVRD
• CIK: 1346830
• Web: N/A
• Phone: (203) 406-3700
• Fax: 203-567-1510
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tvardi Therapeutics: $64.25
• High Price Target: $78.00
• Low Price Target: $52.00
• Potential Upside/Downside: +110.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.87 million
• Net Margins: -678.79%
• Pretax Margin: -453.48%
• Return on Equity: -565.83%
• Return on Assets: -66.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.04
• Quick Ratio: 4.04

Sales & Book Value

• Annual Sales: $7.14 million
• Price / Sales: 40.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.51 per share
• Price / Book: 8.72

Miscellaneous

• Outstanding Shares: 9,380,000
• Free Float: 9,086,000
• Market Cap: $286.93 million
• Optionable: N/A
• Beta: 0.21